BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CBR to Acquire Natera’s Evercord™ Cord Blood Business for an Undisclosed Sum

CBR to Acquire Natera’s Evercord™ Cord Blood Business for an Undisclosed Sum

November 12, 2019 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services.

Discover class-defining bioproduction tools.

Natera’s Evercord™ Cord Blood Business

Natera launched its Evercord™ cord blood business only two years ago in March 2017, in partnership with Bloodworks Northwest, a long-standing public umbilical cord blood banks in the U.S. At the time of its launch, Natera noted: “More than 30,000 cord blood stem cell treatments have been conducted worldwide and Natera’s prenatal tests, including its carrier test, Horizon™, currently screen for 35 of the nearly 80 diseases where cord blood stem cell treatment has been administered.”

In the press release issued about the acquisition of of Natera’s Evercord™ cord blood business by CBR, Steve Chapman, Natera’s CEO, explained: “This divestiture will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology and organ transplantation. We are proud of what we’ve accomplished with Evercord and believe that CBR, as the recognized industry leader in newborn stem cells, is the best partner for cord blood services moving forward.”

bitbio

While it unknown what percent its Evercord™ cord blood business contributed, Natera recently reported a 19% increase it its third quarter (Q3) revenue.

Richard Jenning, the CEO of California Cryobank Life Sciences, shared: “As a pillar of the California Cryobank Life Sciences (CCLS) organization, CBR is built on scientific excellence, leadership, and best-in-class services. Natera shares our core values and commitment to quality. We look forward to safeguarding these newborn stem cells and allowing the Evercord families to take advantage of future advances in cellular therapies and regenerative medicine.”

Pluristyx

History of CBR’s Cord Blood Banking Business

Founded in 1992, Cord Blood Registry (CBR) was acquired by AMAG Pharmaceuticals for $700M in March 2015. By June 2018, AMAG Pharmaceuticals sold its interest in CBR to GI Partners, a private equity investment firm. At the same time it acquired CBR, GI Partners bought California Cryobank, a donor sperm and egg bank. GI Partners then merged the two companies into a single entity providing combination stem cell storage and assisted fertility services.

While many of the smaller banks had been acquiring companies for year, CBR’s acquisition of Natera’s Evercord™ cord blood business was its first direct acquisition of another cord blood banking business.

Do you have questions about CBR’s acquisition of Natera’s Evercord™ cord blood business? Ask them in the comments below.

iPSC-derived cardiomyocte therapy

To learn more about the cord blood market, view the “Global Cord Blood Banking Industry Report.”

5/5 - (5 votes)

Filed Under: Cord Blood, Stem Cell News Tagged With: cord blood, Cord Blood Registry

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.